Search research articles
Contact Us
Filters
Showing results (11-20 of 100) with videos related to
Page
of 10
Sort By:
Treatments in Endocrinology
|
April 19, 2005
Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism
Alex J Brown, Daniel W Coyne
Current Opinion in Nephrology and Hypertension
|
January 10, 2014
Update on intravenous iron choices
Derek S Larson, Daniel W Coyne
Kidney Research and Clinical Practice
|
February 20, 2016
Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease
Derek S Larson, Daniel W Coyne
Kidney International
|
June 16, 2012
Bioavailable vitamin D in chronic kidney disease
Alex J Brown, Daniel W Coyne
Biochemical and Biophysical Research Communications
|
December 14, 1990
Effect of the tyrosine kinase inhibitor, genistein, on interleukin-1 stimulated PGE2 production in mesangial cells
D W Coyne, A R Morrison
Mayo Clinic Proceedings
|
November 3, 2007
Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies
Jay B Wish, Daniel W Coyne
Nephrology Nursing Journal : Journal of the American Nephrology Nurses' Association
|
March 6, 2009
Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate
Daniel W Coyne, Andrea Sims, Brenda Bingel
Seminars in Nephrology
|
May 29, 2016
Iron Treatment Strategies in Dialysis-Dependent CKD
Richa Pandey, Reem Daloul, Daniel W Coyne
American Journal of Nephrology
|
August 19, 2007
ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients
Sijie Zheng, Vijay Nath, Daniel W Coyne
Advances in Chronic Kidney Disease
|
January 18, 2006
Anemia in the kidney-transplant patient
Heidi Joist, Daniel C Brennan, Daniel W Coyne
Page
of 10
Search research articles
Search
Showing results (11-20 of 100) with videos related to
Sort By:
Page
of 10
Treatments in Endocrinology
|
April 19, 2005
Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism
Alex J Brown, Daniel W Coyne
Current Opinion in Nephrology and Hypertension
|
January 10, 2014
Update on intravenous iron choices
Derek S Larson, Daniel W Coyne
Kidney Research and Clinical Practice
|
February 20, 2016
Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease
Derek S Larson, Daniel W Coyne
Kidney International
|
June 16, 2012
Bioavailable vitamin D in chronic kidney disease
Alex J Brown, Daniel W Coyne
Biochemical and Biophysical Research Communications
|
December 14, 1990
Effect of the tyrosine kinase inhibitor, genistein, on interleukin-1 stimulated PGE2 production in mesangial cells
D W Coyne, A R Morrison
Mayo Clinic Proceedings
|
November 3, 2007
Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies
Jay B Wish, Daniel W Coyne
Nephrology Nursing Journal : Journal of the American Nephrology Nurses' Association
|
March 6, 2009
Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate
Daniel W Coyne, Andrea Sims, Brenda Bingel
Seminars in Nephrology
|
May 29, 2016
Iron Treatment Strategies in Dialysis-Dependent CKD
Richa Pandey, Reem Daloul, Daniel W Coyne
American Journal of Nephrology
|
August 19, 2007
ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients
Sijie Zheng, Vijay Nath, Daniel W Coyne
Advances in Chronic Kidney Disease
|
January 18, 2006
Anemia in the kidney-transplant patient
Heidi Joist, Daniel C Brennan, Daniel W Coyne
Page
of 10